ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
May 04, 2023 09:07 ET | ZyVersa Therapeutics
Prolonged systemic inflammation contributes to poor clinical outcomes in severe alcohol-associated hepatitis (“AH”) even after cessation of alcohol useReported data demonstrate a central role of NLRP3...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease
April 10, 2023 09:07 ET | ZyVersa Therapeutics
Increased inflammasome protein expression, NLRP1, NLRP3, ASC, and caspase-1, occurs early in Alzheimer’s disease (AD), indicating a role for multiple types of inflammasomes in disease development...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury
February 23, 2023 09:20 ET | ZyVersa Therapeutics
Data published in Translational Research indicate that pyroptotic release of cytokines and ASC Specks from traumatic brain injury (TBI) induces a heightened inflammasome response in Alzheimer’s...